192 related articles for article (PubMed ID: 36999020)
1. Model for predicting immunotherapy based on M2 macrophage infiltration in TNBC.
Wu H; Feng J; Zhong W; Zouxu X; Xiong Z; Huang W; Zhang C; Wang X; Yi J
Front Immunol; 2023; 14():1151800. PubMed ID: 36999020
[TBL] [Abstract][Full Text] [Related]
2. Identification of Genes Associated with Prognosis and Immunotherapy Prediction in Triple-Negative Breast Cancer via M1/M2 Macrophage Ratio.
Liu J; Deng Y; Liu Z; Li X; Zhang M; Yu X; Liu T; Chen K; Li Z
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512096
[No Abstract] [Full Text] [Related]
3. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
Zhang J; Zhang M; Tian Q; Yang J
Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer.
Liu Z; Ding M; Qiu P; Pan K; Guo Q
Front Immunol; 2023; 14():1200282. PubMed ID: 37520534
[TBL] [Abstract][Full Text] [Related]
6. Novel molecular insights into pyroptosis in triple-negative breast cancer prognosis and immunotherapy.
Yu B; Luo J; Yang Y; Zhen K; Shen B
J Gene Med; 2024 Jan; 26(1):e3645. PubMed ID: 38041540
[TBL] [Abstract][Full Text] [Related]
7. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.
Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247
[TBL] [Abstract][Full Text] [Related]
8. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
[TBL] [Abstract][Full Text] [Related]
9. Development of an ubiquitin-proteasome system signature for predicting prognosis and providing therapeutic guidance for patients with triple-negative breast cancer.
Chen X; Ren C; Zhou Z; Chen J; Fan X; Li X; Chen J; Zhu J
J Gene Med; 2024 Jan; 26(1):e3584. PubMed ID: 37605934
[TBL] [Abstract][Full Text] [Related]
10. Single-cell and bulk RNA sequencing analysis of B cell marker genes in TNBC TME landscape and immunotherapy.
Zhao F; Zhao C; Xu T; Lan Y; Lin H; Wu X; Li X
Front Immunol; 2023; 14():1245514. PubMed ID: 38111587
[TBL] [Abstract][Full Text] [Related]
11. Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer.
Su P; Peng Z; Xu B; Yang B; Jin F
PeerJ; 2021; 9():e12383. PubMed ID: 34900411
[TBL] [Abstract][Full Text] [Related]
12. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.
Zhou Y; Che Y; Fu Z; Zhang H; Wu H
Front Public Health; 2022; 10():902378. PubMed ID: 35875026
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
Qiu P; Guo Q; Yao Q; Chen J; Lin J
Front Immunol; 2021; 12():736030. PubMed ID: 34659224
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer.
Lin F; Huang J; Zhu W; Jiang T; Guo J; Xia W; Chen M; Guo L; Deng W; Lin H
Front Immunol; 2023; 14():1218987. PubMed ID: 37575241
[TBL] [Abstract][Full Text] [Related]
15. A CTL/M2 macrophage-related four-gene signature predicting metastasis-free survival in triple-negative breast cancer treated with adjuvant radiotherapy.
Ye Y; Ma J; Zhang Q; Xiong K; Zhang Z; Chen C; Xiao H; Wang D
Breast Cancer Res Treat; 2021 Nov; 190(2):329-341. PubMed ID: 34482483
[TBL] [Abstract][Full Text] [Related]
16. Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis.
Ma J; Chen C; Liu S; Ji J; Wu D; Huang P; Wei D; Fan Z; Ren L
Cancer Gene Ther; 2022 Nov; 29(11):1578-1589. PubMed ID: 35474355
[TBL] [Abstract][Full Text] [Related]
17. Construction and validation of a macrophage polarization-related prognostic index to predict the overall survival in patients with early-stage triple-negative breast cancer.
Luo H; Hong R; Xu Y; Zheng Q; Xia W; Lu Q; Jiang K; Xu F; Chen M; Shi D; Deng W; Wang S
Gland Surg; 2023 Feb; 12(2):225-242. PubMed ID: 36915811
[TBL] [Abstract][Full Text] [Related]
18. Construction of a prognostic model for triple-negative breast cancer based on immune-related genes, and associations between the tumor immune microenvironment and immunological therapy.
Zhu Y; Tao LF; Liu JY; Wang YX; Huang H; Jiang YN; Qian WF
Cancer Med; 2023 Jul; 12(14):15704-15719. PubMed ID: 37306188
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of comprehensive typing based on m6A and gene cluster in TNBC.
Wu H; Feng J; Wu J; Zhong W; Zouxu X; Huang W; Huang X; Yi J; Wang X
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4367-4380. PubMed ID: 36109402
[TBL] [Abstract][Full Text] [Related]
20. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]